Asset Details
Do you wish to reserve the book?
Prioritizing Parkinson’s disease risk genes in genome-wide association loci
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prioritizing Parkinson’s disease risk genes in genome-wide association loci
Do you wish to request the book?
Prioritizing Parkinson’s disease risk genes in genome-wide association loci
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Prioritizing Parkinson’s disease risk genes in genome-wide association loci
2025
Overview
Many drug targets in ongoing Parkinson’s disease (PD) clinical trials have strong genetic links. While genome-wide association studies (GWAS) nominate regions associated with disease, pinpointing causal genes is challenging. Our aim was to prioritize additional druggable genes underlying PD GWAS signals. The polygenic priority score (PoPS) integrates genome-wide information from MAGMA gene-level associations and over 57,000 gene-level features. We applied PoPS to East Asian and European PD GWAS data and prioritized genes based on PoPS, distance to the GWAS signal, and non-synonymous credible set variants. We prioritized 46 genes, including well-established PD genes (
SNCA
,
LRRK2
,
GBA1
,
TMEM175
,
VPS13C
), genes with strong literature evidence supporting a mechanistic link to PD (
RIT2, BAG3
,
SCARB2, FYN, DYRK1A, NOD2, CTSB, SV2C, ITPKB
), and genes relatively unexplored in PD. Many hold potential for drug repurposing or development. We prioritized high-confidence genes with strong links to PD pathogenesis that may represent our next-best candidates for developing disease-modifying therapeutics.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
